Cara Therapeutics | CARA - Interest Expense On Debt


Cara Therapeutics reported 39.02M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Assertio Holdings USD 758K 1000 Jun/2024
Cara Therapeutics 39.02M 4.73M Sep/2025
Cassava Sciences USD 129.73M 5.65M Sep/2025
Chugai Pharma JPY 95M 260M Dec/2025
Cipla INR 140.3M 8.5M Dec/2025
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
J&J USD 18M 290M Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pacira USD 3.89M 387K Dec/2025
Pfizer USD 711M 59M Dec/2025
RedHill Biopharma USD 89.8K 31.69M Jun/2024
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025